September 28, 2021

Volume XI, Number 271

Advertisement

September 27, 2021

Subscribe to Latest Legal News and Analysis
Advertisement

Belviq Cancer Lawsuits

Weight loss can be a constant struggle and there are some who may benefit from medical interventions to increase their likelihood to lose weight and keep it off.

Belviq (lorcaserin) is a weight-loss drug first approved by the FDA in 2012. It works by affecting brain serotonin to help control the appetite of the user. It was the first weight-loss drug approved by the FDA since 1999.

Belviq was available by prescription only, and a person taking Belviq was supposed to lose 5 percent of their weight during the first 12 weeks taking the drug when coupled with a low-calorie diet. It was also prescribed to overweight people who had serious weight-related health issues such as diabetes and high blood pressure.

At the time of FDA approval, Eisai, the manufacturer, was required to hold a study on the cardiovascular effects of Belviq. However, in 2020, the distributor of Belviq, Eisai, pulled it from the market in the United States at the request of the U.S. Food and Drug Administration.

The FDA found that those who took Belviq are at an increased risk for pancreatic, colorectal and lung cancers. These findings came from a five-year double-blind study of over 12,000 individuals across eight different countries. This study was done at the requirement of the FDA to study the cardiovascular effects of Belviq.

Data from the study showed that 7.7 percent of those taking Belviq developed cancer, while only 7.1 percent of those taking the placebo developed cancer. The study was done to assess the cardiovascular safety of Belviq, but ended up concluding that those that took Belviq had a slight increase in the occurrence of cancers than those we took the placebo.

Due to these findings, the FDA requested Eisai, the manufacturer, to voluntarily pull Belviq from the U.S. market. However, the FDA did not formally recall the product.

Lawyers are actively taking cases for those who took Belviq and were diagnosed with cancer as a result. Lawsuit numbers are growing, it is estimated that hundreds of individuals have developed cancer as a result of Belviq.

Buckfire & Buckfire, P.C. 2021National Law Review, Volume XI, Number 179
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement

About this Author

Larry Buckfire Personal Injury Attorney Buckfire Law
President and Attorney

Lawrence J. Buckfire (Larry Buckfire) earned his undergraduate degree in economics from the University of Michigan in 1986 and his juris doctor degree from Wayne State University School of Law in 1989. He has been in private practice since successfully completing the bar exam in 1989. He is admitted to practice law in the State of Michigan, State of Ohio, and in the United States District Court.

Lawrence is the lead trial attorney and managing partner at Buckfire & Buckfire, P.C.  The law firm was founded in 1969 by his father David Buckfire with the principle of representing...

(855) 365-5999
Advertisement
Advertisement
Advertisement